Scholarlink

<p>COVID-19 may have long lasting cognitive consequences. Studies with a follow-up longer than 1&#xa0;year after infection are lacking. This study presents the prevalence of cognitive impairment 2&#xa0;years after SARS-CoV-2 infection in survivors of the first year of the pandemic and comparison groups matched 1:1 for sex, age, and level of care. Users of the Local Health Unit of Matosinhos (comprising almost all citizens of the municipality) were retrospectively selected according to hospitalization and SARS-CoV-2 infection between March 2020 and February 2021: group #1, hospitalized for COVID-19 (n = 101); group #2, hospitalized, uninfected (n = 87); group #3, non-hospitalized, infected (n = 252); group #4, non-hospitalized, uninfected (n = 258). Between July 2022 and October 2023, all participants completed the Montreal Cognitive Assessment. Those with a score below 1.5 SD of age- and education-specific norms (n = 279) were invited for a comprehensive neuropsychological assessment to identify cognitive impairment. The prevalence of cognitive impairment was higher in group #1 than #2 (19.1% vs. 6.8%; adjusted OR 5.41, 95% CI 1.54, 19.03) and in group #3 than #4 (10.7% vs. 3.2%; adjusted OR 3.27, 95% CI 1.23, 8.67). These results suggest that specific care to timely diagnose and treat cognitive impairment is needed for COVID-19 survivors of the first year of the pandemic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cognitive impairment 2 years after mild to severe SARS-CoV-2 infection in a population-based study with matched-comparison groups

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月8日

查看全文
  • Natália Araújo,
  • Isa Silva,
  • Patrícia Campos,
  • Adriana Costa,
  • Catarina Lopes,
  • Mariana Seco,
  • Ana Rute Costa,
  • Maria Margarida Calejo,
  • Maria Joana Pais,
  • Susana Pereira,
  • Samantha Morais,
  • João Firmino Machado,
  • Luís Ruano,
  • Nuno Lunet,
  • Vítor Tedim Cruz

摘要

COVID-19 may have long lasting cognitive consequences. Studies with a follow-up longer than 1 year after infection are lacking. This study presents the prevalence of cognitive impairment 2 years after SARS-CoV-2 infection in survivors of the first year of the pandemic and comparison groups matched 1:1 for sex, age, and level of care. Users of the Local Health Unit of Matosinhos (comprising almost all citizens of the municipality) were retrospectively selected according to hospitalization and SARS-CoV-2 infection between March 2020 and February 2021: group #1, hospitalized for COVID-19 (n = 101); group #2, hospitalized, uninfected (n = 87); group #3, non-hospitalized, infected (n = 252); group #4, non-hospitalized, uninfected (n = 258). Between July 2022 and October 2023, all participants completed the Montreal Cognitive Assessment. Those with a score below 1.5 SD of age- and education-specific norms (n = 279) were invited for a comprehensive neuropsychological assessment to identify cognitive impairment. The prevalence of cognitive impairment was higher in group #1 than #2 (19.1% vs. 6.8%; adjusted OR 5.41, 95% CI 1.54, 19.03) and in group #3 than #4 (10.7% vs. 3.2%; adjusted OR 3.27, 95% CI 1.23, 8.67). These results suggest that specific care to timely diagnose and treat cognitive impairment is needed for COVID-19 survivors of the first year of the pandemic.